Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I share everyone 's frustration here but most regulatory bodies aren't interested in us PI's and are pretty toothless anyway. In my opinion, patience is required here and we need to wait until the next positive news update. This will send the SP north very quickly. Best not to get too worried about short term movements unless you were looking for a quick trade. We are all well underwater but I believe our day will come in the next 12-18 months. Good luck to all.
186k shares traded during normal hours accompanied by a small rise in the SP. After hours, a further 730k shares traded and we are forecast to be up 30% pre market. Not complaining, but it's hard to get a handle of what's happening here!
The following release has just been issued. The positive is that things are moving forwards, but not sure this will do anything for the price in the short term. A year plus wait to confirm what will be hopefully very positive results.
DALLAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASD:MDAI)
(“Spectral AI” or the “Company”), an artificial intelligence (AI)
company focused on medical diagnostics for faster and more accurate treatment
decisions in clinical wound care, announces the enrollment of the first
patient in the pivotal study to validate DeepView AI(®) using its
proprietary imaging technology for burn size and healing assessment. This
pivotal study is expected to be the final clinical trial before seeking FDA
marketing authorization for the burn indication in 2025 and will be conducted
in burn centers and emergency departments across the US, enrolling both adults
and pediatric patients.
Niko Pagoulatos, Ph.D., Chief Operating Officer of the Company stated: “We
believe this study will further demonstrate the truly innovative and versatile
nature of our technology, as well as its ability to predict burn wound healing
potential on the first day of injury with significantly greater accuracy and
speed than the methods currently used today. We continue to utilize $251
million of non-dilutive government funding since 2019 to validate DeepView for
burn indication, while aggressively advancing other clinical indications like
diabetic foot ulcers in pursuit of our ‘one platform—multiple clinical
indications’ strategy.”
“We are excited to begin enrollment in this pivotal study implementing the
DeepView system in clinical sites across the United States. The study will
help us validate DeepView’s game-changing AI to accurately assess burn wound
healing potential on day-one which could lead to early treatment decisions,”
said Jeffrey C. Carter, MD, FACS, the lead investigator for the study. “This
study is anticipated to deepen the knowledge and understanding of how DeepView
will transform burn care pathways while improving patient outcomes,
concurrently strengthening our country against the challenges of Burn Mass
Casualty Incidents to safeguard and prepare for unforeseen emergencies.”
The data obtained in the study will be compared to assessment by physicians
and used for regulatory submission to the FDA by the first half of 2025.
I am a LTH, but this seems more like a cash raising exercise to avoid dilution and the directors lending more money to the business. We need to widen our sales beyond SLB. My view is we will continue to trend sideways until more contracts with new partners are won.
Interesting article published in the IC today following a meeting in congress. It involves Diversified Energy and their performance on preventing methane leaks on some of their old and abandoned wells. Hopefully, our sales team are all over this.
Members of the US Congress have called for Diversified Energy (DEC) to outline how it is stopping methane leaks from its tens of thousands of mature gas wells.
Four Democratic members of the House Committee on Energy and Commerce wrote to Diversified boss Rusty Hutson Jr on Monday.
“As the largest owner and purchaser of oil and gas wells in the United States, Diversified Energy is responsible for remediating a substantial share of the country’s ageing oil and gas wells, but we are concerned that your company may be vastly underestimating well cleanup costs,” wrote the members.
The company was built on buying up older wells for cheap and running them until dry. Various reports have alleged a lax approach to plugging leaking wells given the sheer scale of Diversified’s portfolio, including a Bloomberg investigation in 2021 that the House committee quotes from extensively.
I am a bit more positive given the outlook and interest from other 3rd parties. Assuming a full year EPS of around 80p leaves us currently currently on a p/e of around 11. The feels way too low given the outlook. We also have the potential of a sale further down the line.
Looking good pre market following the news release below, which was issued after the close.
DALLAS, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, today announced that it will participate in the Benchmark 12th Annual Discovery One-on-One Conference being held on December 7, 2023 in New York City.
Management will participate in 1x1 meetings throughout the day with institutional investors. For more information on the Benchmark 12th Annual Discovery One-on-One Conference, or to schedule a one-on-one meeting, please contact your Benchmark representative or visit the Conference Website
I am with interactive investor and my shares haven't landed yet.
The good news keeps flowing, but the share price continues to drop. The ambition here is big and given the appointment and his worldwide knowledge you have to believe this is going to grow rapidly at some point.
DALLAS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI)
(“Spectral AI” or the “Company”), an artificial intelligence (AI)
company focused on medical diagnostics for faster and more accurate treatment
decisions in wound care, today announced the appointment of Prof. Paul
Chadwick as Executive Vice President of the Company’s United Kingdom
subsidiary. Prof. Chadwick is an experienced clinical scientist and wound care
key opinion leader (KOL) with an impressive body of work including a
substantial and impactful publication record, particularly in the domain of
diabetic wound management. He will be responsible for the international market
expansion of the Company’s DeepView(®) wound imaging technology in the
United Kingdom, Europe, Middle East and Africa (EMEA), all of which are
geographic areas where Prof. Chadwick has extensive clinical networks,
significant experience and has enjoyed previous successes.
“Paul brings over fifteen years of invaluable expertise in the medical
devices and technology sectors to our team. The Royal College of Podiatry is
an extremely prestigious and important organization where Paul most recently
served for over six years in senior executive capacities, including CEO. We
are highly confident that his addition will significantly enhance our efforts
in advancing the widespread adoption of the DeepView(®) System,” said Niko
Pagoulatos, the Company’s COO. “Spectral AI continues to strengthen its
leadership team and Paul’s experience in diabetic foot ulcers and clinical
wound management will contribute to our growth and enhance our capacity to
innovate.”
Prof. Chadwick’s impressive journey stretches across clinical, academic and
business disciplines. In his previous roles at the Royal College of Podiatry,
Prof. Chadwick led all the clinical, educational and financial aspects of the
organization. In addition, he has held multiple leadership positions such as
consultant podiatrist at The National Health Service (NHS), and Managing
Director at Curativo Wound Care Consultancy, where he has served companies
such as 3M, Molnlycke Health Care, Smith & Nephew, Advancis, Thornton & Ross,
Essity and many others. In his capacity as a prominent authority in wound
care, Prof. Chadwick fulfills critical roles on advisory boards and
exemplifies best practices in the field. Furthermore, he generously imparts
his knowledge as an adjunct professor at Birmingham City University, where he
teaches in the Health and Life Sciences Department.
No. Rang up ii last week and they said there had been a problem at their end but this had now been resolved and the shares should be with me early this week, but still nothing.
MDAI have just delivered the following guidance
Financial Guidance
* Research & Development Revenue (“Revenue”) for FY2023 is expected to
approximate $17.4 million
* Revenue for FY2024 is expected to approximate $28.0 million
“We are on the cusp of delivering a distinct, cutting-edge AI-driven wound
healing assessment platform with the potential to significantly improve the
current standard of care across multiple indications,” said Wensheng Fan,
CEO of Spectral AI. “As we continue to advance our burn indication, we are
as excited about the prospects for the use of DeepView(®) for DFU, an
estimated $11.0 billion market that we believe is in dire need of a solution
that provides clinicians with an immediate healing assessment for more
accurate and timely diagnosis and therapeutic intervention. We intend to
submit applications for FDA, UKCA, and CE mark approval for the DeepView(®)
DFU indication, as well as for 3D wound measurement capabilities, in FY2024
subject to the completion of ongoing studies.”
The Company noted that the financial guidance for FY2024 does not reflect the
material financial contributions it expects would result from the
commercialization of DeepView(®) for DFU and 3D wound measurement following
the receipt of necessary regulatory clearances. As previously disclosed, the
Company has received regulatory approval for the DeepView SnapShot(®) device
and the Company will now seek the approval of its integrated AI application to
obtain both UKCA and FDA approval for the commercialization of the complete
DeepView SnapShot(®) System in the United States and across the globe.
“We believe we are in the best position in our history to deliver
significant value for patients dealing with acute and chronic wound
conditions, physicians and health systems that are challenged with effectively
and cost-efficiently managing these conditions, and, of course, our
shareholders,” Mr. Fan concluded.